Drug Approval | February 21, 2025
Korea’s MFDS completes inspection at Concord Biotech's Dholka unit
The inspection was successfully completed
The inspection was successfully completed
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
No safety signals related to the vaccine candidate were identified
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Approval is based on positive data from the Phase 3 ECHELON-3 trial
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Subscribe To Our Newsletter & Stay Updated
